Back
ESC Premium Access

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Session: Congress committee e-posters choice in heart failure
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Speaker: Doctor J. Kolwelter (Erlangen, DE)
Event: ESC Congress 2021 - The Digital Experience

Congress Session

0

About the speaker

Doctor Julie Kolwelter

University Hospital Erlangen, Erlangen (Germany)
0 follower

46 more presentations in this session

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Speaker: Doctor A. Sharma (Montreal, CA)

Access
Abstract
Slides
0
Thumbnail

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Speaker: Doctor V. Razuk (New York, US)

Access
Abstract
Slides
0
Thumbnail

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Speaker: Doctor G. Gager (Vienna, AT)

Access
Abstract
Slides
0
Thumbnail

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Speaker: Doctor M. Senni (Bergamo, IT)

Access
Abstract
Slides
0
Thumbnail

Empagliflozin reduces TNFa-induced reactive oxygen species through inhibition of the human endothelial Na+/H+ exchanger 1

Speaker: Doctor L. Uthman (Nijmegen, NL)

Access
Abstract
Slides
0
Thumbnail

Access the full session

Congress committee e-posters choice in heart failure

Speakers: Doctor J. Kolwelter, Doctor A. Sharma, Doctor V. Razuk, Doctor G. Gager, Doctor M. Senni...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Replacing the pill: the future of CVD therapy.

27 August 2021

ESC Premium Access

The ECG and beyond: artificial intelligence will penetrate cardiology practice.

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

This platform is supported by

logo Novo Nordisk